EU distances itself from Ribera's claims of Israeli genocide in Gaza
ADVERTISEMENT
ADVERTISEMENT
More about this topic
AstraZeneca beats expectations and raises guidance despite China woes
AstraZeneca raises its fiscal 2024 guidance for the second consecutive quarter. This upgrade comes despite ongoing legal challenges in China as it reported robust third-quarter earnings results.
AstraZeneca leads in valuation as it bets on cancer drugs portfolio
The company has tied up with Eccogene, a Chinese biotech firm, for a new experimental weight loss drug. The weight loss market is currently dominated by Eli Lilly and Novo Nordisk.
AstraZeneca announces a billion-dollar cancer plant in Singapore
The new factory highlights a rising trend by pharmaceutical companies to develop production facilities in local markets, to ensure a smoother supply chain and further cement their regional influence.
AstraZeneca stock up as it pulls Covid-19 vaccine from European market
The pharma giant AstraZeneca has requested that the European authorisation for its Covid-19 vaccine be pulled, according to the EU medicines regulator.
ADVERTISEMENT
AstraZeneca asks for European approval of COVID jab to be pulled
AstraZeneca was one of the first pharma laboratories to launch a COVID vaccine on the market at the end of 2020, a year after the virus appeared.
AstraZeneca reports bumper revenue in Q1 2024 on strong drug demand
AstraZeneca continued to see strong earnings boosted primarily by its oncology branch, as well as its respiratory and immunology segment.
AstraZeneca CEO set to earn £18.7 million after shareholder backing
More than 60% of shareholders backed the decision to raise Pascal Soriot’s pay packet, solidifying his position as the highest earning FTSE 100 boss.
AstraZeneca shares tumble despite posting strong sales for cancer drug
Shares in AstraZeneca were down nearly 4% on the London Stock Exchange on Thursday morning after reporting its latest financial results.
Have healthcare stocks been under the weather in 2023?
Euronews Business looks at how major healthcare stocks such as Pfizer and Moderna performed this year
Davos 2022: Is the world ready to fight off the next health crisis?
Preparing the world for another health crisis is a hot topic in Davos this week. Euronews Next spoke to AstraZeneca about lessons learned from COVID.
Here’s what COVID vaccine makers are doing about the Omicron variant
COVID vaccine manufacturers are racing to develop new doses to combat the rising number of cases connected to the Omicron variant.
COVID vaccines: Scientists may have solved mystery of rare blood clots
The AstraZeneca and Johnson & Johnson coronavirus vaccines are associated with extremely rare cases of blood clots - and now scientists think they may know what’s behind this.
EU ends legal dispute with AstraZeneca over vaccine delays
The Commission and the company have struck a deal to guarantee all the 300 million doses will be delivered by the end of March 2022.
Blood clot risk from vaccines ‘much lower’ than those from COVID-19
A new study by the BMJ found there was an increased risk of rare blood clots associated with AstraZeneca and Pfizer’s vaccine, but that risk was much higher in patients who tested positive for coronavirus.
COVID-19 booster shots already underway in several countries
Some countries are starting to offer a third dose of the COVID-19 vaccine for the most vulnerable, in an attempt to combat the spread of the Delta variant.
AstraZeneca and Pfizer COVID vaccines have 'similar' blood clot risk
Researchers in Barcelona found both jabs carried a similarly low risk of blood clots, while people infected with COVID-19 were much more likely to develop them.